Navigation Links
HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting

Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including, but not limited to, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/4/2008)...X-351 awarded orphan designation for the treatment...eukemia, PRINCETON, N.J., Sept. 4 /-...U.S. Food & Drug Administration (FDA) has granted ...norubicin) Liposome Injection,for the treatment of...tly preparing to conduct two randomized Phase 2,st...
(Date:9/4/2008)...her Roche first in TaqMan(R) real-time PCR testing... lab, PLEASANTON, Calif., Sept. 4 /PRNewswire/ ...pproved the Roche COBAS(R) TaqMan(R) HBV Test,the...A approved in the U.S.,The test uses Roche,s real-...titis B virus DNA in a patient,s blood. Doctors ma...
(Date:9/4/2008)...ractice Bulletin for Obstetrician-Gynecologists St...ice Change-Minimally Invasive Interventional,Radio... With Uterine,Fibroids, FAIRFAX, Va., Sept. 4 /PR...nal Radiology, a national organization of nearly 4...ionals dedicated to improving health,care through ...
(Date:9/4/2008)...tal Study Seeks to Enroll 750 Women at More Than 1...- QuatRx Pharmaceuticals, a,privately...ment and,commercialization of compounds to treat e...today announced that it has initiated a second,Pha...ets), the company,s,estrogen-free oral therapy in ...
Breaking Medicine Technology:Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 1NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 2NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 3NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 4Steroids Seem Safe for Babies at Risk of Early Birth 1618 1Steroids Seem Safe for Babies at Risk of Early Birth 1618 2Steroids Seem Safe for Babies at Risk of Early Birth 1618 3Pennsylvania Needs More Lung Cancer Research 1615 1STAAR Surgical Reports Operational Progress 1612 1STAAR Surgical Reports Operational Progress 1612 2STAAR Surgical Reports Operational Progress 1612 3STAAR Surgical Reports Operational Progress 1612 4
...IRE)--Apr 30, 2007 - CollaGenex,Pharmaceuticals, I...t in the May 2007 issue of the Journal of the Amer...zed phase III clinical trials,demonstrated the ef...cline (Oracea(R), 40-mg doxycycline, USP capsules)...cluded these studies,establish the first important...
...IRE)--Apr 30, 2007 - Hemispherx Biopharma,Inc. (A...lication,(Journal of Immunology, April 2007) that ...proprietary experimental therapeutic,Ampligen(R) ...g,tested as a monotherapy for Chronic Fatigue Synd...s., The new peer-reviewed study shows conclusively...
Other Medicine Technology:Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4New Report Illuminates Ampligen's Unique Mechanism of Action 2New Report Illuminates Ampligen's Unique Mechanism of Action 3New Report Illuminates Ampligen's Unique Mechanism of Action 4
(Date:9/4/2008).... Free drug samples provided to physicians by pha...insured patients more in the long run, according t...rsity Baptist Medical Center and colleagues. , T...abits of more than 70 physicians in a university-a... immediately before and after the closing of their...
(Date:9/4/2008)...n a case-control study, the presence of measles vi... and GI disturbances than in children with only GI... onset were unrelated to MMR vaccine timing. Stud...ary of Science on September 4 ( http://dx.plos.or... implementation of measles vaccines in 1963, three...
(Date:9/4/2008)...ence of instructions they say could help doctors e...lthDay News) -- Vaccine safety experts say that al...eive vaccinations with close monitoring and a set ...ptember issue of Pediatrics , a team of experts l...h a step-by-step set of instructions -- an algorit...
(Date:9/4/2008)...ger labeling about fungal infection risk , ...l health authorities have asked the manufacturers ...ster safety warnings on the risk of developing opp...ra, Cimzia, Enbrel and Remicade, belong to a class...ha blockers (TNF-alpha blockers), which suppress t...
Breaking Medicine News(10 mins):Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...olocaust are more likely to suffer from cancer and...d his colleagues at Israel's //Haifa University su...ear-starvation of European Jews during World War I...at the incidence and death rate from cancer in aro...
... of Goan’s can be the main cause for HIV/AIDS spre...ollow the Government policies // and initiatives t...Many labourers who got jobs in Goa, since it has b...ing with them the dreadful virus (HIV) when they a...
...er gave Isabelle Taylor, of St Annes, Lancs, a mob... grand child would end up constantly // sending te...loping a condition known as ‘repetitive strain in...n in Britain to suffer from this condition. Her m...
... researchers plan to ask women to donate their egg... cells matched to patients // which they say would...ng diseases such as diabates or neurodegenerative ...nic stem (ES) cells after creating human embryos c...
Other Medicine News:
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing.
Medicine Products: